whatshot

OPK   $1.57  0.64% Market Closed After Close 1.6 1.91%

OPKO Health Inc
show_chart Advanced Chart of OPK
Last Events:

2024-01-05 The hottest instrument.

2023-08-09 Trend pattern changed from сужающийся канал to канал.

2023-08-09 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's lower than the signal line and falls. These factors mean that negative mood prevails. Last signal: down-crossing the middle level.

2023-08-09 Signal in RSI changed from bullish to bearish. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA20 changed from bullish reversal to bearish reversal. The price is trying to cross down the moving average line If the intersection will be successful, then a downside trend can be formed.

2023-08-09 Trend Power changed from strong to medium strength.

2023-08-06 Signal in MACD changed from bearish to bearish weakening. Oscillator MACD is in the negative territory it's lower than the signal line and grows. These factors mean that the falling trend persists, but the growth rate is declining. Last signal: down-crossing the middle level.

2023-08-06 Signal in RSI changed from bearish weakening to bullish. RSI indicator is in the upper part of the neutral territory and it grows. These factors indicate that positive dynamics persists. Last signal: entrance to the overbought zone.

Current temperature: 16.92
ST: 0, Cor:

50-50 Year Forecast
Low with % probability:
Target: 1.44
High with % probability:
Analyst Recommendations:
Number of estimates 6
Target Price Mean 3.96
Mean unverified/preliminary 3.96 / 3.96
Target Price Low / High 2.00 / 8.50
Median / STD DEV 3.00 / 2.46
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total ActivelyBuy ActivelyBuy ActivelyBuy
rsi ActivelyBuy None None
macd None None None
stoch None None None
ma20 ActivelyBuy ActivelyBuy ActivelyBuy
ma50 None None None
ma100 ActivelyBuy ActivelyBuy ActivelyBuy
Candlestick PatternNov. 19, 2024 Long Legged - consists of a Doji with very long upper and lower shadows. Indicates strong forces balanced in opposition.
ISIN US68375N1037
ceo Dr. Phillip Frost Ph.D.
Website https://www.opko.com
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.